New immune cell therapy offers hope for kids with Tough-to-Treat leukemia
NCT ID NCT06064903
Summary
This study is testing a new cell therapy called CD7-CART01 in children and young adults (6 months to 25 years old) whose T-cell leukemia or lymphoma has come back or hasn't responded to standard treatments. Doctors will first find the safest dose and then see if the treatment can put the cancer into remission. The therapy involves collecting a patient's own immune cells, engineering them in a lab to better target cancer, and then infusing them back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Rome, 00165, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.